China’s Harbour BioMed has struck a deal worth more than US$1.2 billion with a clinical-stage biotechnology company to develop and commercialise an antibody outside China, as the country’s novel drug makers increasingly secure not only upfront licensing fees but also long-term international partnerships.
The Shanghai-based company announced a licence and equity agreement on Monday with Solstice Oncology, a firm established by a syndicate of venture capital investors, for the exclusive…
